Home › Funds › Renaissance Technologies › UTHR
Renaissance Technologies position in UTHR
UNITED THERAPEUTICS CORP DEL · Health Care
Renaissance Technologies reported holding 1,675,899 shares of UTHR (UNITED THERAPEUTICS CORP DEL) in its Q3 2026 13F filing — a position valued at US$908.2M, representing 1.24% of its reported portfolio and ranking #3 among its reported holdings. Renaissance Technologies has disclosed UTHR holdings in 55 of the last 55 reported quarters, going back to Q1 2013.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How Renaissance Technologies's UTHR position evolved
Renaissance Technologies first disclosed a stake in UTHR in Q1 2013 at 323,175 shares (US$19.7M). The position peaked in Q1 2026 at 1,787,019 shares, worth US$1.06B. Across 55 filings, Renaissance Technologies increased the stake 27 time(s), trimmed it 26 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 1,675,899 shares valued at US$908.2M — a reduction of -32,840 shares quarter over quarter.. Notable position changes include a 99% trim in Q3 2014, a 7690% increase in Q4 2014, a 141% increase in Q1 2015.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2013 | 323.18K | $19.67M | New |
| Q2 2013 | 590.38K | $38.86M | Add |
| Q3 2013 | 440.78K | $34.76M | Reduce |
| Q4 2013 | 224.28K | $25.36M | Reduce |
| Q1 2014 | 287.94K | $27.07M | Add |
| Q2 2014 | 252.48K | $22.34M | Reduce |
| Q3 2014 | 2.38K | $306.00K | Reduce |
| Q4 2014 | 185.24K | $23.99M | Add |
| Q1 2015 | 446.50K | $76.99M | Add |
| Q2 2015 | 811.58K | $141.17M | Add |
| Q3 2015 | 866.78K | $113.76M | Add |
| Q4 2015 | 552.08K | $86.46M | Reduce |
| Q1 2016 | 474.58K | $52.88M | Reduce |
| Q2 2016 | 404.30K | $42.82M | Reduce |
| Q3 2016 | 390.10K | $46.06M | Reduce |
| Q4 2016 | 421.20K | $60.41M | Add |
| Q1 2017 | 506.20K | $68.53M | Add |
| Q2 2017 | 837.60K | $108.66M | Add |
| Q3 2017 | 1.27M | $149.18M | Add |
| Q4 2017 | 1.46M | $216.36M | Add |
| Q1 2018 | 1.53M | $172.35M | Add |
| Q2 2018 | 1.56M | $176.08M | Add |
| Q3 2018 | 1.94M | $248.61M | Add |
| Q4 2018 | 2.20M | $239.23M | Add |
| Q1 2019 | 2.24M | $263.12M | Add |
| Q2 2019 | 3.04M | $237.38M | Add |
| Q3 2019 | 3.21M | $256.18M | Add |
| Q4 2019 | 3.54M | $312.19M | Add |
| Q1 2020 | 3.59M | $340.44M | Add |
| Q2 2020 | 3.73M | $450.94M | Add |
| Q3 2020 | 3.71M | $374.61M | Hold |
| Q4 2020 | 3.61M | $547.55M | Reduce |
| Q1 2021 | 3.21M | $536.53M | Reduce |
| Q2 2021 | 3.11M | $558.00M | Reduce |
| Q3 2021 | 3.03M | $559.02M | Reduce |
| Q4 2021 | 2.92M | $630.35M | Reduce |
| Q1 2022 | 2.77M | $496.11M | Reduce |
| Q2 2022 | 2.79M | $658.28M | Add |
| Q3 2022 | 2.55M | $533.96M | Reduce |
| Q4 2022 | 2.34M | $651.98M | Reduce |
| Q1 2023 | 2.23M | $498.85M | Reduce |
| Q2 2023 | 2.19M | $482.83M | Reduce |
| Q3 2023 | 2.25M | $508.32M | Add |
| Q4 2023 | 2.17M | $477.21M | Reduce |
| Q1 2024 | 2.15M | $494.29M | Reduce |
| Q2 2024 | 2.17M | $692.75M | Add |
| Q3 2024 | 2.16M | $772.38M | Reduce |
| Q4 2024 | 2.09M | $737.22M | Reduce |
| Q1 2025 | 2.11M | $649.52M | Add |
| Q2 2025 | 2.12M | $608.92M | Add |
| Q3 2025 | 2.17M | $911.11M | Add |
| Q4 2025 | 1.91M | $930.29M | Reduce |
| Q1 2026 | 1.79M | $1.06B | Reduce |
| Q2 2026 | 1.71M | $925.85M | Reduce |
| Q3 2026 | 1.68M | $908.15M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About UTHR and 13F data
UTHR (UNITED THERAPEUTICS CORP DEL) is a Health Care company. 38 other funds we track also report a position in UTHR — the largest reported positions include Avoro Capital Advisors LLC (US$1.51B), ASSETMARK, INC (US$325.2M), DEERFIELD MANAGEMENT COMPANY, L.P. (US$247.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding UTHR
- Avoro Capital Advisors LLC 2.78M sh · $1.51B · Q2 2026
- ASSETMARK, INC 600.17K sh · $325.23M · Q3 2026
- DEERFIELD MANAGEMENT COMPANY, L.P. 457.00K sh · $247.62M · Q2 2026
- Vestal Point Capital, LP 435.00K sh · $235.70M · Q2 2026
- Eversept Partners, LP 287.67K sh · $155.87M · Q2 2026
More on Renaissance Technologies
FAQ
How long has Renaissance Technologies held UTHR?
Renaissance Technologies has disclosed UTHR holdings in 55 of the last 55 reported quarters, going back to Q1 2013.
What is Renaissance Technologies's current position in UTHR?
As of Q3 2026, Renaissance Technologies holds 1.68M shares of UTHR (UNITED THERAPEUTICS CORP DEL), valued at $908.15M, representing 1.24% of its reported portfolio and ranking #3.
Has Renaissance Technologies been buying or selling UTHR?
In the latest 13F filing (Q3 2026), Renaissance Technologies reduced its position in UTHR. The position peaked in Q1 2026 at 1.79M shares.
Which other funds hold UTHR?
Other major institutional holders of UTHR include Avoro Capital Advisors LLC, ASSETMARK, INC, DEERFIELD MANAGEMENT COMPANY, L.P., among 38 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.